Mesorectal Microbiome and Metabolome as a Prognostic Factor in Patients With Rectal Cancer and Analysis of it's Applicability in Neoadjuvant Treatment
The equilibrium of intestinal microorganisms is essential for health an imbalance has been associated with an increased risk in the development of different pathologies; including colorectal cancer. Rectal cancer is the third most common neoplasm worldwide and the complete excision of the mesorectum is a major prognostic factor. The identification of microorganisms in the adipose tissue that surrounds the small intestine in inflammatory diseases, together with bacterial alterations found in colonic mucosa and feces in patients with rectal cancer in comparison with healthy individuals indicates that microbiome alteration plays an essential role in pathogenesis. The mesorectal microbiome in rectal cancer patients stills unknown and given its importance in the prognostic of the disease the goal of this study is to identify microbial profiles that allow predicting rectal cancer patients with a poor prognosis.
• Patients with colorectal cancer that will undergo elective surgery
• Patients diagnosed with non-oncological disease with an indication for elective surgery.
• Age ≥ 18 years
• Histology proven adenocarcinoma or adenoma with or without chemotherapy or neoadjuvant radiochemotherapy
• Tumoral stage equal or grater than T1
• Attempt to R0 resection
• Signed informed consent by the patient and by the researcher
• Dietary Questionnaire completed